Welcome to our dedicated page for Seres Therapeutics SEC filings (Ticker: MCRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Seres Therapeutics, Inc. (MCRB) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents include Form 8-K current reports, which Seres uses to announce quarterly financial results, operational updates, leadership changes, cost-reduction actions, and other material events.
For a clinical-stage live biotherapeutics company like Seres, SEC filings are a primary source of information on the status of its programs and financial position. In recent 8-K filings, the company has reported results and updates related to its lead investigational candidate SER-155, including descriptions of Phase 1b data in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT), regulatory designations such as Breakthrough Therapy and Fast Track, and ongoing interactions with the U.S. Food and Drug Administration regarding a planned Phase 2 study design.
Filings also discuss the company’s classification of historical VOWST™ operating results as discontinued operations following the sale of that asset to Nestlé Health Science, as well as the provision of manufacturing services under a Transition Services Agreement. Additional disclosures cover cash runway expectations, workforce reductions, and business development efforts aimed at securing capital or strategic partnerships to advance SER-155 and other live biotherapeutic candidates.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand topics such as trial plans, risk factor discussions, and material corporate actions. Users can review 8-Ks and other filings in real time as they are posted to EDGAR, and use AI-generated insights to interpret how Seres’ regulatory and financial disclosures relate to its live biotherapeutics pipeline and overall strategy.
MCRB Form 144 notice reports proposed sales of Common restricted and performance shares totaling 8,553 shares, with venue indicated as NASDAQ. The filing shows 75 Common shares sold by Teresa L. Young on 02/17/2026 at $635.25 per share. The excerpt lists 9,586,298 shares with a date of 03/17/2026 (as shown in the row).
Seres Therapeutics, Inc. has scheduled its 2026 annual meeting of stockholders for June 9, 2026. Stockholders who hold common shares as of the close of business on April 13, 2026 will be entitled to vote at the meeting.
Because the 2026 meeting will occur more than 30 days after the 2025 meeting anniversary, the company has set a revised deadline for qualified stockholder proposals under SEC Rule 14a-8. Proposals must be received at the company’s principal executive office by the close of business on March 26, 2026 to be considered for inclusion in the 2026 proxy statement.
Seres Therapeutics files its annual report describing a shift toward early-stage microbiome drugs while warning of substantial doubt about its ability to continue as a going concern. The company says it will need additional funding or partnerships and may pursue alternatives including potential bankruptcy or a wind-down.
Seres sold rights to its approved microbiome drug VOWST to Nestlé Health Science in 2024 and is now focused on live biotherapeutic candidates SER-155, SER-603, SER-147 and a liquid ICU formulation. Phase 1b data for SER-155 in allo-HSCT showed a 77% relative risk reduction in bacterial bloodstream infections and won Fast Track and Breakthrough Therapy designations, but a planned Phase 2 trial is paused pending financing.
Seres Therapeutics reported fourth quarter and full year 2025 results and outlined its microbiome pipeline strategy. For 2025, the company generated $0.8 million in grant revenue and recorded $5.7 million in net income from continuing operations, driven largely by an $80.7 million gain on the sale of its VOWST business and lower operating expenses of $94.8 million versus $121.3 million in 2024.
As of December 31, 2025, Seres held $45.8 million in cash and cash equivalents and expects this to fund operations through the third quarter of 2026, while it seeks partnerships and other financing. The company is prioritizing live biotherapeutic programs for inflammatory and immune diseases, including SER-155, which showed a 77% relative risk reduction in bloodstream infections in a Phase 1b allo-HSCT study and is Phase 2 ready, and SER-603 for inflammatory bowel disease. An investigator-sponsored SER-155 trial in immune checkpoint inhibitor–related enterocolitis is fully enrolled, with data expected in the second quarter of 2026.
Seres Therapeutics, Inc. reported that officer Kelly Brady received a grant of stock options for 56,250 shares of common stock on March 4, 2026. The options have an exercise price of $9.13 per share and are held as a direct derivative position.
The option grant vests over time: 25% of the shares vest on March 2, 2027, with the remaining shares vesting in 12 equal quarterly installments after that date. This is a compensation-related award rather than an open-market stock purchase or sale.
Seres Therapeutics insider Brady Kelly has filed an initial ownership report showing existing equity holdings in the company. The filing lists several stock options to purchase Common Stock, including one covering 11,700 shares at an exercise price of 15.6400 per share expiring on February 6, 2035, plus additional options with exercise prices around 22.0000 to 23.0000 per share expiring in 2034. Kelly also holds Restricted Stock Units tied to 358 and 730 shares of Common Stock and directly owns 8,441 shares of Common Stock following the reported positions. The footnotes explain that these options and RSUs vest over time, with 25% already vested and the remainder scheduled to vest in 12 equal quarterly installments after the initial vesting dates.
Kender Richard N reported acquisition or exercise transactions in this Form 4 filing.
Seres Therapeutics, Inc. director and officer Richard N. Kender reported receiving a grant of stock options covering 150,000 shares of common stock. These options give him the right to buy company shares and were reported as a direct beneficial holding.
According to the filing, the option award vests and becomes exercisable in 36 equal monthly installments, providing long-term, incremental equity-based compensation tied to his continued service with the company.
Seres Therapeutics, Inc. disclosed that officer Matthew R. Henn received a grant of stock options covering 75,000 shares of common stock on March 4, 2026. These options give him the right to buy company shares if they vest and are exercised in the future.
According to the vesting schedule, 25% of the option shares will vest on March 2, 2027, with the remaining shares vesting in 12 equal quarterly installments thereafter. This filing reflects an equity-based compensation award rather than an open-market share purchase or sale.
Seres Therapeutics, Inc. reported that officer Marella Thorell received a grant of stock options covering 22,500 shares of the company’s stock. This is classified as a grant or award acquisition, not a market purchase or sale.
According to the vesting terms, 25% of the option shares will vest on March 2, 2027, with the remaining shares vesting in 12 equal quarterly installments after that date. Following this grant, Thorell’s directly held option position from this award totals 22,500 option shares.
DesRosier Thomas reported acquisition or exercise transactions in this Form 4 filing.
Seres Therapeutics, Inc. reported that officer Thomas DesRosier received a grant of stock options covering 22,500 shares of the company’s stock. No cash was paid for this award, which is described as a “Stock Option (right to buy).”
According to the vesting terms, 25% of the option shares will vest on March 2, 2027. The remaining shares will then vest in 12 equal quarterly installments after that date, tying the award to continued service over several years.